Literature DB >> 21805675

Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer.

Richard T Bryan1, Wenbin Wei, Neil J Shimwell, Stuart I Collins, Syed A Hussain, Lucinda J Billingham, Paul G Murray, Nayneeta Deshmukh, Nicholas D James, D Michael A Wallace, Philip J Johnson, Maurice P Zeegers, K K Cheng, Ashley Martin, Douglas G Ward.   

Abstract

PURPOSE: There is a need for better biomarkers to both detect bladder cancer and distinguish muscle-invasive (stage T2+) from non-invasive (stage Ta/T1) disease. We assess whether MALDI-TOF-MS of the urine peptidome can achieve this. EXPERIMENTAL
DESIGN: We analysed urine from 751 patients with bladder cancer and 127 patients without bladder cancer. Endogenous peptide profiling was performed using a Bruker Ultraflextreme MALDI-TOF-MS.
RESULTS: Significant differences were seen between the spectra of urine from patients with and without T2+ disease. Albumin, total protein and haematuria were also elevated in T2+ patients. Haematuria was detected in 39% of patients with Ta/T1 disease and in 77% of patients with T2+ disease. Class prediction models based on MALDI data produced areas under receiver-operator characteristic curves of up to 0.76 but did not significantly outperform a model based on total protein alone. Many peptides significantly associated with invasive disease are fragments of abundant blood proteins and are also associated with haematuria. CONCLUSIONS AND CLINICAL RELEVANCE: Microscopic haematuria is strongly associated with invasive disease; even traces of blood/plasma strongly influence the urinary peptidome. This needs to be taken into consideration when using 'omic' methods to search for urinary biomarkers as blood proteins may give false-positive results.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21805675     DOI: 10.1002/prca.201100011

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  10 in total

Review 1.  Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers.

Authors:  Steven L Wood; Margaret A Knowles; Douglas Thompson; Peter J Selby; Rosamonde E Banks
Journal:  Nat Rev Urol       Date:  2013-02-26       Impact factor: 14.432

Review 2.  Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena.

Authors:  Richard T Bryan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-02-05       Impact factor: 6.237

3.  Use of Aleuria alantia Lectin Affinity Chromatography to Enrich Candidate Biomarkers from the Urine of Patients with Bladder Cancer.

Authors:  Sarah R Ambrose; Naheema S Gordon; James C Goldsmith; Wenbin Wei; Maurice P Zeegers; Nicholas D James; Margaret A Knowles; Richard T Bryan; Douglas G Ward
Journal:  Proteomes       Date:  2015-09-03

Review 4.  Liquid biopsy: a step forward towards precision medicine in urologic malignancies.

Authors:  Ashley Di Meo; Jenni Bartlett; Yufeng Cheng; Maria D Pasic; George M Yousef
Journal:  Mol Cancer       Date:  2017-04-14       Impact factor: 27.401

5.  Defining the frequency of human papillomavirus and polyomavirus infection in urothelial bladder tumours.

Authors:  Matthew A Llewellyn; Naheema S Gordon; Ben Abbotts; Nicholas D James; Maurice P Zeegers; K K Cheng; Andrew Macdonald; Sally Roberts; Joanna L Parish; Douglas G Ward; Richard T Bryan
Journal:  Sci Rep       Date:  2018-07-26       Impact factor: 4.379

6.  Patients choose certainty over burden in bladder cancer surveillance.

Authors:  Frits H M van Osch; Duncan Nekeman; Neil K Aaronson; Lucinda J Billingham; Nicholas D James; K K Cheng; Richard T Bryan; Maurice P Zeegers
Journal:  World J Urol       Date:  2019-03-23       Impact factor: 4.226

7.  Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma.

Authors:  N J Shimwell; R T Bryan; W Wei; N D James; K K Cheng; M P Zeegers; P J Johnson; A Martin; D G Ward
Journal:  Br J Cancer       Date:  2013-04-16       Impact factor: 7.640

8.  A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer.

Authors:  Jamie J D'Costa; James C Goldsmith; Jayne S Wilson; Richard T Bryan; Douglas G Ward
Journal:  Bladder Cancer       Date:  2016-07-27

Review 9.  Proteomics and peptidomics: moving toward precision medicine in urological malignancies.

Authors:  Ashley Di Meo; Maria D Pasic; George M Yousef
Journal:  Oncotarget       Date:  2016-08-09

Review 10.  MALDI-TOF/MS Analysis of Non-Invasive Human Urine and Saliva Samples for the Identification of New Cancer Biomarkers.

Authors:  Carlo Zambonin; Antonella Aresta
Journal:  Molecules       Date:  2022-03-16       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.